Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis

Song Yee Kim, Jungho Kim, Deok Ryun Kim, Young Ae Kang, Sungyoung Bong, Jonghee Lee, Suyeon Kim, Nam Suk Lee, Bora Sim, Sang Nae Cho, Young Sam Kim, Hyejon Lee

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Background: Prior to clinical trials of new TB drugs or therapeutic vaccines, it is necessary to develop monitoring tools to predict treatment outcomes in TB patients. Urine interferon gamma inducible protein 10 (IP-10) is a potential biomarker of treatment response in chronic hepatitis C virus infection and lung diseases, including tuberculosis. In this study, we assessed IP-10 levels in urine samples from patients with active TB at diagnosis, during treatment, and at completion, and compared these with levels in serum samples collected in parallel from matched patients to determine whether urine IP-10 can be used to monitor treatment response in patients with active TB. Methods: IP-10 was measured using enzyme-linked immunosorbent assays in urine and serum samples collected concomitantly from 23 patients with active TB and 21 healthy adults (44 total individuals). The Mann-Whitney U test and Wilcoxon matched-pairs signed rank test were used for comparisons among healthy controls and patients at three time points, and LOESS regression was used for longitudinal data. Results: The levels of IP-10 in urine increased significantly after 2 months of treatment (P = 0.0163), but decreased by the completion of treatment (P = 0.0035). Serum IP-10 levels exhibited a similar trend, but did not increase significantly after 2 months of treatment in patients with active TB. Conclusions: Unstimulated IP-10 in urine can be used as a biomarker to monitor treatment response in patients with active pulmonary TB.

Original languageEnglish
Article number240
JournalBMC Infectious Diseases
Issue number1
Publication statusPublished - 2018 May 29

Bibliographical note

Funding Information:
This study was supported by a grant from the Korean Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), founded by the Ministry for Health, Welfare, and Family Affairs, Republic of Korea (A101750 and HI14C1324) and by the Basic Science Research Program through the National Research Foundation of Korea (NRF), founded by the Ministry of Science, ICT and Future Planning (NRF-2015K1A3A7A03073714).

Publisher Copyright:
© 2018 The Author(s).

All Science Journal Classification (ASJC) codes

  • Infectious Diseases


Dive into the research topics of 'Urine IP-10 as a biomarker of therapeutic response in patients with active pulmonary tuberculosis'. Together they form a unique fingerprint.

Cite this